Mulla, C
Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus
Submit a New Drug Application (NDA): Eli Lilly is expected to submit a New Drug Application (NDA) to the FDA for obesity if the Phase III program is successful
When the medicine is eventually approved, prescribers will follow the MHRA-approved Summary of Product Characteristics
GLP-1 medications have multiple different mechanisms in the body that help with diabetes and weight loss, including: Increasing the amount of insulin made by the pancreas , which helps control blood sugar in patients with diabetes Decreasing the amount of excess sugar made by the pancreas , which helps control blood sugar in patients with diabetes Slowing down digestion from the stomach , which results in feeling full for longer after eating Signaling to your brain that you are full after eating , which helps suppress appetite and control cravings Tirzepatide contains an extra mechanism of action that other GLP-1 medications do not, known as GIP (glucose-dependent insulinotropic polypeptide) agonism
Related Reporting on Weight Management Options For readers exploring the broader weight management landscape, the following third-party reporting provides additional context on different product categories: Analysis of telehealth GLP-1 supplier options - Third-party reporting on compounded semaglutide access through telehealth platforms
